Prevalence and specificity of some rare red cell pan-reactive alloantibodies against high frequency red cell antigens among hospitalized Saudi patients

Samy Attallah; Tarek Hakeem; Ebrahim Hamdy; Zyiad AlHarby; Faisal Althubiani; Ershad Dade; Abdulla Al Harbi

Prevalence and specificity of some rare red cell pan-reactive alloantibodies against high frequency red cell antigens among hospitalized Saudi patients

View Full Text View/Add Comment Download reader

DOI：10.46701/BG.2020022020126

KeyWord:pan-reactive alloantibody, high-frequency antigen, blood transfusion

Author	Institution
Samy Attallah	Medical Laboratory Department, King Fahad Armed Forces Hospital, Jeddah 9862-21159, Saudi Arabia; Clinical Pathology Department, Mansoura University, Mansoura city 35514, Egypt.
Tarek Hakeem	Medical Laboratory Department, King Fahad Armed Forces Hospital, Jeddah 9862-21159, Saudi Arabia.
Ebrahim Hamdy	Medical Laboratory Department, King Fahad Armed Forces Hospital, Jeddah 9862-21159, Saudi Arabia.
Zyiad AlHarby	Medical Laboratory Department, King Fahad Armed Forces Hospital, Jeddah 9862-21159, Saudi Arabia.
Faisal Althubiani	Medical Laboratory Department, King Fahad Armed Forces Hospital, Jeddah 9862-21159, Saudi Arabia.
Ershad Dade	Medical Laboratory Department, King Fahad Armed Forces Hospital, Jeddah 9862-21159, Saudi Arabia.
Abdulla Al Harbi	Medical Laboratory Department, King Fahad Armed Forces Hospital, Jeddah 9862-21159, Saudi Arabia.

Hits: 1554

Download times: 1583

Abstract:

Some patients' sera react with all available donors' red cells and a compatible donor is difficult or impossible to be found. These may either be due to a complex mixture of antibodies or the presence of alloantibodies against high-frequency antigens (HFAs). The aim of this study is to identify the prevalence and characteristics of antibodies to HFAs in Saudi Arabian patients. A total of 23 out of 172 000 patients who received blood transfusions had rare alloantibodies to HFAs at an incidence of 0.013%. Twenty-three patients suspected with pan-reactive alloantibodies against HFAs had their red cells tested using antisera to HFAs, while their plasma was tested against a selected panel of red blood cells with rare phenotypes. Anti-Ge2 antibody was found in the highest number of patients (56.5%), whereas anti-U, anti JK3, anti H, anti-RH 29, anti-hr^s, anti-Kn^a, anti-Ch, anti-Rg, anti-Yt^a, and anti-Cr^a antibodies were found in the remaining patients (43.5%). This study suggests that although antibodies such as anti-Ge2, anti- Kn^a, anti-Ch, anti-Rg, anti-Yt^a , and anti-Cr^a are not clinically significant, they cause a delay in the provision of compatible blood. Whereas, anti-U, anti JK3, anti H, anti-RH29 and anti-hr^s are clinically significant antibodies. An understanding of antibody characteristics to HFAs and the widespread use of the extended red cell phenotype and antibody identification panel will both be helpful for the diagnosis of these HFAs.